01273 704473

info@novuscomms.com

01273 704473

info@novuscomms.com

Vela Technologies #VELA – Update re. investment in Conduit Pharmaceuticals Inc. August 9, 2024 – Posted in: Vela Technologies Plc (VELA)

The Board of Vela (AIM: VELA), an AIM-quoted investing company focused on early stage and pre-IPO disruptive technology investments, notes the announcement released by Conduit Pharmaceuticals Inc. (“Conduit”) on 8 August 2024 regarding Conduit entering into an exclusive licence agreement with AstraZeneca for multiple assets to advance potential first-in-class treatments. Vela holds 1,005,760 common shares in Conduit representing 0.46% of Conduit’s issued share capital. At the closing mid-market price of $0.17 on 8 August 2024,…

Continue reading

Vela Technologies #VELA investee co Conduit Pharmaceuticals Inks Licensing Pact With AstraZeneca For Multiple Assets August 8, 2024 – Posted in: Blog, Vela Technologies Plc (VELA)

Vela Technologies #VELA is pleased to note that investee company Conduit Pharmaceuticals has entered into an agreement with AstraZeneca Plc (NASDAQ:AZN) to exclusively license rights to develop AZD1656 and AZD5658, both HK-4 glucokinase activators and AZD5904, a myeloperoxidase inhibitor (MPO). AstraZeneca had progressed AZD1656 and AZD5904 through Phase 1 clinical trials. Conduit initially intends to conduct Phase 2 clinical trials on candidates AZD1656 and AZD5658 in 2024 for applications in autoimmune disorders. Under the terms of the License Agreement,…

Continue reading

Vela Technologies #VELA – Investee co Conduit Pharmaceuticals secures $2.65 million funding – Posted in: Vela Technologies Plc (VELA)

Vela Technologies #VELA is pleased to note that investee pharmaceutical co Conduit Pharmaceuticals Inc. (NASDAQ:CDT) has entered into a financing agreement securing $2.65 million through a Senior Secured Promissory Note with Nirland Limited. The agreement, effective Monday, includes an issuance of 12.5 million shares of common stock to the purchaser. The promissory note carries an annual interest rate of 12%, accruing daily, with the option for the purchaser to receive interest payments in cash or…

Continue reading

Vela Technologies #VELA – Conduit Pharmaceuticals Receives Patent Approval For Its Lead Asset Targeting Autoimmune Diseases July 17, 2024 – Posted in: Vela Technologies Plc (VELA)

Read here Conduit Pharmaceuticals Inc. (Nasdaq: CDT) today announced the approval of a composition of matter patent application by IP Australia, achieving successful examination of a patent on its lead asset, an HK-4 Glucokinase Activator which targets a wide range of autoimmune diseases. The Company is enrolled to participate in the Patent Prosecution Highway (PPH), a program to fast-track patent examination in major jurisdictions including the U.S., Europe and Japan. Since IP Australia has allowed…

Continue reading

Vela Technologies #VELA – Put Option for potential sale of Economic Interest in AZD1656 April 20, 2023 – Posted in: Blog, Vela Technologies Plc (VELA)

The Board of Vela (AIM: VELA), an AIM-quoted investing company focused on early-stage and pre-IPO disruptive technology investments, is pleased to announce that the Company has today entered into a put option agreement (“the Option Agreement”) to give the Company the right, but not the obligation (“the Option”), to sell its economic interest in the commercialisation of the Covid-19 application of AZD1656 for a total consideration of £4.0 million. The Option is being granted by…

Continue reading

Vela Technologies #VELA – Update re. AZD1656 November 9, 2022 – Posted in: Blog, Vela Technologies Plc (VELA)

The Board of Vela (AIM: VELA), an AIM-quoted investing company focused on early-stage and pre-IPO disruptive technology investments, notes the announcement made yesterday evening by Conduit Pharmaceuticals Limited (“Conduit”) that it intends to become a publicly traded company on NASDAQ in the USA via a merger with Murphy Cannon Acquisition Corp. (“Murphy”), a NASDAQ-listed special purpose acquisition company. Vela holds an economic interest in the commercialisation of a particular application of AZD1656, one of the…

Continue reading